Jessica Harness
Urology · Castle Rock, CONPI 1598027336
Payments from drug & device makers
Across 91 payments — averaging $73.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Procept Biorobotics Corporation$769
- Covidien LP$625
- Medtronic$565
- Coloplast$378
- Teleflex LLC$365
- plus $879 from 13 others
What the payments were for
- Consulting fees$6259%
- Travel & lodging$3,31249%
- Food & beverage$2,65040%
- Education$1092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 28 | $3,115 |
| Procept Biorobotics Corporation | 4 | $769 |
| Covidien LP | 1 | $625 |
| Medtronic | 4 | $565 |
| Coloplast | 8 | $378 |
| Teleflex LLC | 6 | $365 |
| Axonics, Inc. | 7 | $165 |
| Bayer | 1 | $124 |
| Myovant Sciences Inc. | 6 | $112 |
| Antares Pharma, Inc. | 6 | $80 |
| Astellas Pharma US Inc | 4 | $75 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Ambu Inc. | 3 | $56 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $52 |
| Convatec Inc. | 3 | $47 |
| Urovant Sciences Inc | 2 | $39 |
| Dendreon Pharmaceuticals LLC | 1 | $38 |
| 180 Medical, Inc. | 1 | $14 |
| Urogen Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lumenis Pulse 120H$1,306
- GENERAL BPH$998
- AquaBeam Robotic System$738
- Sonicision$625
- GENERAL KIDNEY STONE DISEASE$161
- UroLift System$150
- ALTIS$138
- Xofigo$124
- GENERAL - THERAPIES$124
- TITAN$103
How this compares
$6,696 in reported general payments places this provider in the 70th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 18 | $156,630 |
| MyrbetriqMirabegron | 163 | $124,326 |
| GemtesaVibegron | 72 | $52,127 |
| Estradiol | 66 | $6,514 |
| Methenamine Hippurate | 72 | $6,086 |
| Mirabegron ErMirabegron | 12 | $6,030 |
| Potassium Citrate ErPotassium Citrate | 32 | $2,084 |
| Tamsulosin Hcl | 107 | $1,082 |
| Cephalexin | 71 | $1,037 |
| Trimethoprim | 14 | $960 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $921 |
| Finasteride | 63 | $597 |
| Testosterone Cypionate | 16 | $389 |
| Oxybutynin Chloride | 19 | $334 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $75 | $280,956181 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $65 | $52,12772 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 225 urology providers in Colorado.
Other urology in Castle Rock
- Dayne NelsonCastle Rock$8K
- David CahnGolden$12.1M
- Lawrence KarshDenver$9.7M
- Alexandra RogersLafayette$541K
- Derek ZukoskyGolden$442K
- Paul MaroniAurora$234K
- James McBrideDurango$234K
- James FagelsonLittleton$229K
- Damian SorceParker$224K
- Michael FerrandinoWestminster$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.